首页|法舒地尔联合尤瑞克林治疗脑梗死后血管性认知障碍临床研究

法舒地尔联合尤瑞克林治疗脑梗死后血管性认知障碍临床研究

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的 探讨法舒地尔联合尤瑞克林治疗脑梗死后血管性认知障碍(VCI)的临床疗效及对患者脑血流灌注、神经电生理指标及同型半胱氨酸(Hcy)的影响。方法 选取医院 2020 年 6 月至 2022 年 12 月收治的脑梗死后VCI患者 116 例，根据治疗方案的不同分为观察组(69 例)和对照组(47 例)。两组患者均接受常规抗血小板聚集治疗及注射用尤瑞克林静脉滴注，观察组患者加予盐酸法舒地尔注射液静脉滴注。两组均持续治疗 2 个月。结果 观察组总有效率为 91。30%，显著高于对照组的 76。60%(P<0。05)。与对照组比较，观察组患者治疗后的脑基底的脑血流量、脑血容量显著增加，平均通过时间显著缩短，P300 波幅显著增大，P300 潜伏期显著缩短，脑电波比值[(δ + θ)/(α + β)]、血清Hcy水平显著降低(P<0。05)。观察组与对照组不良反应发生率相当(13。04%比 8。51%，P>0。05)。结论 法舒地尔联合尤瑞克林治疗脑梗死后VCI，能改善患者的脑血流灌注及神经电生理功能指标，降低Hcy水平。
Clinical Study of Fasudil Combined with Urinary Kallidinogenase in the Treatment of Vascular Cognitive Impairment After Cerebral Infarction
Objective To investigate the clinical efficacy of fasudil combined with urinary kallidinogenase in the treatment of vascular cognitive impairment(VCI)after cerebral infarction,and its effect on the cerebral blood flow perfusion,neuroelectrophysiological indexes and homocysteine(Hcy)in patients.Methods A total of 116 patients with VCI after cerebral infarction admitted to the hospital from June 2020 to December 2022 were selected and divided into the observation group(69 cases)and the control group(47 cases)according to different treatment regimens.The patients in the two groups were given routine anti-platelet aggregation therapy and intravenous drip of Urinary Kallidinogenase for Injection,on this basis,the patients in the observation group were given intravenous drip of Fasudil Hydrochloride Injection.Both groups were treated continuously for two months.Results The total effective rate in the observation group was 91.30%,which was significantly higher than 76.60%in the control group(P<0.05).Compared with those in the control group,the cerebral blood flow(CBF)and cerebral blood volume(CBV)significantly increased,mean transit time(MTT)significantly shortened,P300 amplitude significantly increased,P300 latency significantly shortened,(δ + θ)/(α + β)and Hcy level significantly decreased(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(13.04%vs.8.51%,P>0.05).Conclusion Fasudil combined with urinary kallidinogenase can improve the cerebral blood flow perfusion and neuroelectrophysiological indexes,and decrease the Hcy level in patients with VCI after cerebral infarction.

fasudilurinary kallidinogenasecerebral infarctionvascular cognitive impairmentcerebral blood flow perfusionneuroelectrophysiological functionhomocysteineclinical efficacy

宋旭、杨汉文、黄杰英、王芹、杨姣、刘银花

展开 >

济宁医学院附属医院,山东 济宁 272007

湘雅博爱康复医院,湖南 长沙 410000

山东中医药大学第二附属医院,山东 济南 250001

法舒地尔 尤瑞克林 脑梗死 血管性认知障碍 脑血流灌注 神经电生理功能 同型半胱氨酸 临床疗效

山东省中医药科技项目

M-2023102

2024

10.3969/j.issn.1006-4931.2024.08.022

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子：1.369
ISSN：1006-4931
年,卷(期)：2024.33(8)
  • 18